Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0UJMPA)
| ADC Name |
BA1302
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BA1302
Click to Show/Hide
|
|||||
| Organization |
BioRay Biopharmaceutical (Boan Biotech) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-CD228 antibody
|
Antibody Info | ||||
| Antigen Name |
Melanotransferrin (MELTF)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
MC-β-Ala-(glucuronide)-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
BNLD11
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Pancreatic cancer | ||||
| Lung cancer | ||||
| Melanoma | ||||
| Breast cancer |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion criteria require histologically confirmed metastatic/unresectable solid tumors (Part A: any advanced solid tumors; Part B: specific cancers including melanoma, breast cancer, NSCLC, or pancreatic adenocarcinoma) with progression after standard therapy, ECOG ≤1, measurable disease by RECIST v1.1, and available tumor tissue for biomarker analysis. Exclusions comprise other active malignancies within 5 years (except certain cured cancers), recent anticancer treatments (≤28 days), severe drug hypersensitivity, pregnancy/lactation, or conditions compromising safety/study compliance.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06596915 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of BA1302 in Patients With Advanced Solid Malignancies | ||||
| Primary Endpoint |
The primary safety endpoints include the number of participants experiencing dose-limiting toxicities (DLTs) within the first 21 days and adverse events (AEs) recorded through 28 days after the last treatment.
|
||||
| Other Endpoint |
Key secondary endpoints focus on pharmacokinetics (AUC0-t, AUC0-inf, Cmax, t1/2, and AUC at steady state) and immunogenicity (ADA incidence), all evaluated over approximately one year. Efficacy measures comprise objective response rate (ORR) and duration of response (DOR) per RECIST v1.1.
|
||||